Evolus (EOLS) Consolidated Net Income (2017 - 2026)
Evolus' (EOLS) quarterly Consolidated Net Income came in at -$10.7 million in Q1 2026, up 43.5% YoY from -$7.4 million in Q1 2025, and down 8310.77% on a QoQ basis from $130000.0 in Q4 2025.
Evolus (EOLS) Consolidated Net Income (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Consolidated Net Income data on file, last reported at -$10.7 million in Q1 2026.
- Quarterly Consolidated Net Income rose 43.5% year-over-year to -$10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.4 million (up 22.74% YoY) and the FY2025 annual result came in at -$51.6 million, down 2.42% from the prior year.
- Consolidated Net Income retreated to -$10.7 million in Q1 2026, from $130000.0 in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $130000.0 in Q4 2025 to a low of -$23.5 million in Q2 2022.
- A 5-year average of -$14.6 million and a median of -$15.7 million in 2025 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income plunged 373.41% — and 2025, when it soared 101.91%.
- Tracing EOLS's Consolidated Net Income over 5 years: stood at -$13.2 million in 2022, then rose by 10.13% to -$11.8 million in 2023, then jumped by 42.6% to -$6.8 million in 2024, then surged by 101.91% to $130000.0 in 2025, then slumped by 8310.77% to -$10.7 million in 2026.
- The last three Consolidated Net Income figures came in at -$10.7 million (Q1 2026), $130000.0 (Q4 2025), and -$15.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Evolus | 550.84 Mn | 505.67 Mn | 57.18 Mn | -8.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.05 Mn |
| Mar 31, 2026 | -10.67 Mn |
| Dec 31, 2025 | 130,000.00 |
| Sep 30, 2025 | -15.74 Mn |
| Jun 30, 2025 | -17.14 Mn |
| Mar 31, 2025 | -18.89 Mn |
| Dec 31, 2024 | -6.79 Mn |
| Sep 30, 2024 | -19.17 Mn |
| Jun 30, 2024 | -11.35 Mn |
| Mar 31, 2024 | -13.11 Mn |
| Dec 31, 2023 | -11.83 Mn |
| Sep 30, 2023 | -16.92 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Mar 31, 2023 | -14.79 Mn |
| Dec 31, 2022 | -13.16 Mn |
| Sep 30, 2022 | -20.28 Mn |
| Jun 30, 2022 | -23.47 Mn |
| Mar 31, 2022 | -17.50 Mn |
| Dec 31, 2021 | -18.18 Mn |
| Sep 30, 2021 | -19.43 Mn |